Abstract
We discuss the analysis of the myelosuppressive effects of chemotherapy. Such analyses examine hematologic data that arise by monitoring patients after treatment with high doses of chemotherapy. We propose a flexible approach for modeling such information and, using data collected as part of a Phase I study of an anticancer agent, show some interesting aspects of the data that become available after fitting models this way.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
M. J. Ratain, R. L. Schilsky, B. A. Conley, and M. J. Egorin. Pharmacodynamics in cancer therapy.J. Clin. Oncol. 8:1739–1753 (1990).
J. S. Penta, G. L. Rosner, and D. L. Trump. Choice of starting dose and escalation for Phase I studies of antitumor agents.Cancer Chemother. Pharmacol. 31:247–250 (1992).
R. Mick and M. J. Ratain. Modelling interpatient pharmacodynamic variability of etoposide.J. Natl. Cancer Inst. 83:1560–1564 (1991).
D. L. Trump, M. J. Egorin, A. Forrest, J. K. V. Willson, S. Remick, and K. D. Tutsch. Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continous infusion with and without dipyridamole.J. Clin. Oncol. 9:2027–2035 (1991).
S. M. Lichtman, M. J. Ratain, D. A. Van Echo, G. Rosner, M. J. Egorin, D. R. Budman, N. J. Vogelzang, L. Norton, and R. L. Schilsky. Granulocyte-macrophage colony stimulating factor (GM-CSF) plus high-dose biweekly cyclophosphamide: A Cancer and Leukemia Group B phase I study.J. Natl. Cancer Inst. 85:1319–1326 (1993).
W. P. Peters, G. Rosner, M. Ross, J. Vredenburgh, B. Meisenberg, C. Gilbert, and J. Kurtzberg. Comparative effects of granulocyte-macrophage colony stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy.Blood 81:1709–1719 (1993).
J. Crawford, H. Ozer, R. Stoller, D. Johnson, G. Lyman, I. Tabbara, M. Kris, J. Grous, V. Picozzi, G. Rausch, R. Smith, W. Gradishar, A. Yahanda, M. Vincent, M. Stewart, and J. Glaspy. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.New Engl. J. Med. 325:164–170 (1991).
M. J. Egorin, D. A. Van Echo, S. J. Tipping, E. A. Olman, M. Y. Whitacre, B. W. Thompson, and J. Aisner. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function.Cancer Res. 44:5432–5438 (1984).
R. D. Cook and S. Weisberg.Residuals and Influence in Regression. Chapman and Hall, London, UK, 1982.
G. A. F. Seber and C. J. Wild.Nonlinear Regression, Wiley, New York, 1989.
L. B. Sheiner and T. H. Grasela, Jr.. An introduction to mixed effect modeling: Concepts, definitions, and justification.J. Pharmacokin. Biopharm. 19 (Suppl):11s-24s (1991).
M. J. Crowder and D. J. Hand.Analysis of Repeated Measures, Chapman and Hall, London, UK, 1990.
S. L. Beal and L. B. Sheiner. Estimating population kinetics.CRC Crit. Rev. Biomed. Eng. 8:195–222 (1982).
M. L. Lindstrom and D. M. Bates. Nonlinear mixed effects models for repeated measures data.Biometrics 46:673–687 (1990).
E. F. Vonesh and R. L. Carter. Mixed effects nonlinear regression for unbalanced repeated measures.Biometrics 48:1–18 (1992).
A. Mallet, F. Mentré, J-L. Steimer, and F. Lokiec. Nonparametric maximum likelihood estimation for population pharmacokinetics, with application to cyclosporine.J. Pharmacokin. Biopharm. 16:311–327 (1988).
M. Davidian and A. R. Gallant. Smooth nonparametric maximum likelihood estimation for population pharmacokinetics, with application to quinidine.J. Pharmacokin. Biopharm. 20:529–556 (1992).
G. E. P. Box and G. C. Tiao.Bayesian Inference in Statistical Analysis (Wiley classics library edition), Wiley, New York, 1992.
B. D. Ripley.Stochastic Simulation, Wiley, New York, 1987, Section 4.7.
A. E. Gelfand and A. F. M. Smith. Sampling-based approaches to calculating marginal densities.J. Am. Stat. Assoc. 85:398–409 (1990).
A. F. M. Smith and G. O. Roberts. Bayesian computation via the Gibbs sampler and related Markov chain Monte Carlo methods.J. R. Stat. Soc. B 55:3–23 (1993).
L. Tierney. Markov chains for exploring posterior distributions (with discussion).Ann. Statist. 22:1701–1762 (1994).
G. Casella and E. I. George. Explaining the Gibbs sampler.Am. Statist. 46:167–174 (1992).
W. K. Hastings. Monte Carlo sampling methods using Markov chains and their applications.Biometrika 57:97–109 (1970).
A. Gelman and D. Rubin. Inference from iterative simulation using multiple sequences.Statist. Sci. 7:457–473 (1992).
J. Geweke. Evaluating the accuracy of sampling-based approaches to the calculation of posterior moments. In J. M. Bernardo, J. O. Berger, A. P. Dawid, and A. F. M. Smith (eds),Bayesian Statistics 4, Oxford University Press, Oxford, UK, 1992, pp. 169–194.
A. E. Gelfand, D. K. Dey, and H. Chang. Model determination using predictive distributions with implementations via sampling-based methods. In J. M. Bernardo, J. O. Berger, A. P. Dawid, and A. F. M. Smith (eds.),Bayesian Statistics 4, Oxford University Press, Oxford, UK, 1992, pp. 147–167.
P. McCullagh and J. A. Nelder.Generalized Linear Models, 2nd ed. Chapman and Hall, London, UK, 1989.
S. L. Zeger and M. R. Karim. Generalized linear models with random effects; A Gibbs sampling approach.J. Am. Statist. Soc. 86:79–86 (1991).
Author information
Authors and Affiliations
Additional information
Supported, in part, by grants from the American Cancer Society (ACS-IRG 158H) and the NCI through the Cancer and Leukemia Group B.
Rights and permissions
About this article
Cite this article
Rosner, G.L., Müller, P. Pharmacodynamic analysis of hematologic profiles. Journal of Pharmacokinetics and Biopharmaceutics 22, 499–524 (1994). https://doi.org/10.1007/BF02353792
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02353792